Chiesi are an international company with a strong focus on innovative medicines in Respiratory, Neonatology, Special Care and Rare Diseases including the first stem cell therapy and the first gene therapy in Europe.
Transplantation is the latest therapy area for Chiesi and a key part of a growing Special Care portfolio. With Chiesi’s commitment to education and research we look forward to working with the BTS for many years to come.
Astellas Pharma Inc. is a global pharmaceutical company with a simple vision – to produce exceptional medicines that change tomorrow for patients in need. Headquartered in Tokyo, Astellas was founded in 2005 through the merger of Yamanouchi and Fujisawa, marrying nearly two centuries of collective experience in producing pharmaceutical drugs.
We combine the deep expertise brought by this long heritage with the forward-thinking outlook of a young company.
Established in 1993, family-owned company PHARMAPAL supplies an array of pharmaceuticals and organ transplantation products in the United Kingdom, Southeast Europe and the MENA region. Operating in the UK since 2014, we are committed to upholding to the principles of Good Distribution Practice (GDP), and pride ourselves in providing outstanding service to customers in a reliable and efficient manner.
PHARMAPAL is the sole distributor of CUSTODIOL® (HTK), an internationally renowned solution of choice in multi-organ transplantation and heart preservation.
Sandoz, a Novartis division, is a world leader in generic pharmaceuticals and biosimilars, finding innovative ways to make high-quality medicines affordable, without compromising on patient management.
For over 30 years, the combined Novartis organisation has been committed to the field of transplantation, bringing new treatments to market to individualise therapy and optimize patient outcomes.